Henry Schein (HSIC)
(Delayed Data from NSDQ)
$70.82 USD
+0.98 (1.40%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $70.80 -0.02 (-0.03%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$70.82 USD
+0.98 (1.40%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $70.80 -0.02 (-0.03%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth C Momentum A VGM
Zacks News
Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's What Key Metrics Tell Us About Henry Schein (HSIC) Q1 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Henry Schein (HSIC) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Henry Schein (HSIC) Tops Q1 Earnings, Lowers '24 Sales View
by Zacks Equity Research
Henry Schein's (HSIC) first-quarter performance reflects a strong recovery from last year's cyber incident.
Henry Schein (HSIC) Surpasses Q1 Earnings Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 11.11% and 1.76%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Henry Schein (HSIC) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Henry Schein (HSIC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.
West Pharmaceutical Services (WST) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 20.93% and 3.27%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Align Technology (ALGN) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Align Technology (ALGN) delivered earnings and revenue surprises of 8.08% and 2.62%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Henry Schein (HSIC) Gears Up for Q1 Earnings: Factors to Note
by Zacks Equity Research
Henry Schein's (HSIC) first-quarter 2024 results are likely to indicate a strong sales recovery post last year's cybersecurity incident.
Henry Schein (HSIC) Global Presence Aids, Macroeconomic Woes Stay
by Zacks Equity Research
Henry Schein (HSIC) is busy promoting digital workflows for general dentistry and dental specialties.
Here's Why You Should Retain Henry Schein (HSIC) Stock for Now
by Zacks Equity Research
Favorable Dental business trends and expansion efforts through acquisitions and partnerships bode well for Henry Schein (HSIC).
Henry Schein (HSIC) Buys TriMed to Expand in Orthopedic Space
by Zacks Equity Research
According to Henry Schein (HSIC), the upper and lower extremities are among the fastest-growing segments of orthopedics, representing a total addressable market of more than $5.5 billion.
Why Is Henry Schein (HSIC) Down 1.8% Since Last Earnings Report?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Compared to Estimates, Henry Schein (HSIC) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Henry Schein (HSIC) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Henry Schein (HSIC) Q4 Earnings Miss, Operating Margin Down
by Zacks Equity Research
Henry Schein (HSIC) posts lower-than-expected earnings and revenues in the fourth quarter of 2023.
Henry Schein (HSIC) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of -5.71% and 1.83%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Seeking Clues to Henry Schein (HSIC) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Henry Schein (HSIC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
Henry Schein (HSIC) Set to Post Q4 Earnings: What Awaits?
by Zacks Equity Research
Henry Schein's (HSIC) fourth-quarter 2023 results are likely to reflect the resiliency of the dental and medical markets amid macroeconomic challenges.
Henry Schein (HSIC) Sales Hurt by Cyber Attack, Macro Woes
by Zacks Equity Research
Henry Schein's (HSIC) financial operations are being affected by the current macroeconomic environment.
Henry Schein (HSIC) Enters Orthopedic Market With New Buyout
by Zacks Equity Research
Henry Schein's (HSIC) recent deals will position it as a prominent producer and supplier in the orthopedic market's Foot and Ankle, Hand and Wrist extremity sectors.
Henry Schein (HSIC) Up 4.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Henry Schein's (HSIC) Zahn Dental and Myerson Enter New Deal
by Zacks Equity Research
Henry Schein's (HSIC) dental laboratory business, Zahn Dental, is set to exclusively distribute Myerson's New Trusana 3D Premium Denture System.
Henry Schein (HSIC) Q3 Revenues Miss, 2023 Guidance Cut
by Zacks Equity Research
Henry Schein's (HSIC) third-quarter 2023 performance demonstrates remarkable sales growth in the Technology and Value-Added Service businesses.
Compared to Estimates, Henry Schein (HSIC) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Henry Schein (HSIC) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Henry Schein (HSIC) Matches Q3 Earnings Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 0% and 0.93%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Insights Into Henry Schein (HSIC) Q3: Wall Street Projections for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Henry Schein (HSIC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2023.